MYB and adrenal cortex carcinoma: A phase 2 trial of ATRA in advanced ACC showed a correlation between suppressed MYB and prolonged stable disease as a response to ATRA, but patients with low MYB expression showed better responses (longer PFS) to ATRA therapy than patients with high MYB levels, suggesting a more efficient MYB-suppressing activity of ATRA when MYB expression is low[208].